{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:20:46Z","timestamp":1781299246688,"version":"3.54.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Haas Family Foundation"},{"name":"Millennium Pharmaceuticals Inc"},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceutical Company Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020124","name":"Seagen Inc","doi-asserted-by":"crossref","award":["SGN35-IST-r001"],"award-info":[{"award-number":["SGN35-IST-r001"]}],"id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100020124","name":"Seagen Inc","doi-asserted-by":"crossref","award":["SGN35-IST-030"],"award-info":[{"award-number":["SGN35-IST-030"]}],"id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100020124","name":"Seagen Inc","doi-asserted-by":"crossref","award":["SGN35-IST-002"],"award-info":[{"award-number":["SGN35-IST-002"]}],"id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21-CA74117"],"award-info":[{"award-number":["R21-CA74117"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Anderson Cancer Center Core","award":["CA16672-22"],"award-info":[{"award-number":["CA16672-22"]}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K24 CA 86815"],"award-info":[{"award-number":["K24 CA 86815"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cutaneous T-Cell Lymphoma"},{"name":"Patient Education and Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The safety and efficacy of brentuximab vedotin (BV), an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials in patients with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell non-Hodgkin lymphoma (NHL). The objective of this research was to examine the relationship between CD30 expression level and clinical response to BV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>We analyzed response in patients treated with BV monotherapy in 5 prospective clinical studies in relapsed or refractory PTCL, CTCL, or B-cell NHL. CD30 expression was assessed by immunohistochemistry (IHC) using the Ber H2 antibody for 275 patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Across all 5 studies, 140 (50.9%) patients had tumors with CD30 expression &amp;lt;10%, including 60 (21.8%) with undetectable CD30 by IHC. No significant differences were observed for any study in overall response rates between patients with CD30 expression \u226510% or &amp;lt;10%. Median duration of response was also similar in the CD30 \u226510% and &amp;lt;10% groups for all studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this analysis of studies across a range of CD30-expressing lymphomas, CD30 expression alone, as measured by standard IHC, does not predict clinical benefit from BV, making the determination of a threshold level of expression uncertain.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac137","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T22:25:40Z","timestamp":1660170340000},"page":"864-873","source":"Crossref","is-referenced-by-count":46,"title":["Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1772-0659","authenticated-orcid":false,"given":"Deepa","family":"Jagadeesh","sequence":"first","affiliation":[{"name":"Cleveland Clinic , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Siteman Cancer Center , St. Louis, MO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cancer Institute , Stanford, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Little","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc. , Cambridge, MA , USA (a wholly owned subsidiary of Takeda Pharmaceuticals Limited)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Trepicchio","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc. , Cambridge, MA , USA (a wholly owned subsidiary of Takeda Pharmaceuticals Limited)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keenan","family":"Fenton","sequence":"additional","affiliation":[{"name":"Seagen Inc. , Bothell, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Onsum","sequence":"additional","affiliation":[{"name":"Seagen Inc. , Bothell, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lisano","sequence":"additional","affiliation":[{"name":"Seagen Inc. , Bothell, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute , Stanford, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"issue":"1","key":"2022100119173343700_CIT0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511","article-title":"Cd30 (ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy","volume":"85","author":"Falini","year":"1995","journal-title":"Blood"},{"issue":"2","key":"2022100119173343700_CIT0002","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/clim.1998.4636","article-title":"Cd30 in normal and neoplastic cells","volume":"90","author":"Chiarle","year":"1999","journal-title":"Clin Immunol"},{"issue":"8","key":"2022100119173343700_CIT0003","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"Cd30 expression in peripheral t-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"2022100119173343700_CIT0004","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/978-0-387-89520-8_12","article-title":"Chapter 12: targeting cd30\/cd30l in oncology and autoimmune and inflammatory diseases","volume":"647","author":"Oflazoglu","year":"2009","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"2022100119173343700_CIT0005","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/PAS.0b013e3181bf677d","article-title":"Cd30 expression and proliferative fraction in nontransformed mycosis fungoides","volume":"33","author":"Edinger","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2022100119173343700_CIT0006","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjh.13085","article-title":"Cd30 expression in de novo diffuse large b-cell lymphoma: a population-based study from british columbia","volume":"167","author":"Slack","year":"2014","journal-title":"Br J Haematol"},{"issue":"11","key":"2022100119173343700_CIT0007","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.3109\/10428194.2013.778407","article-title":"Frequency and extent of cd30 expression in diffuse large b-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases","volume":"54","author":"Campuzano-Zuluaga","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"2022100119173343700_CIT0008","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","article-title":"Cd30 expression defines a novel subgroup of diffuse large b-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the international dlbcl rituximab-chop consortium program study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"32","key":"2022100119173343700_CIT0009","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase ii investigator-initiated study of brentuximab vedotin in mycosis fungoides and sezary syndrome with variable cd30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl_15","key":"2022100119173343700_CIT0010","doi-asserted-by":"crossref","first-page":"Abstract 7538","DOI":"10.1200\/JCO.2019.37.15_suppl.7538","article-title":"Response to a+chp by cd30 expression in the echelon-2 trial","volume":"37","author":"Advani","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"2022100119173343700_CIT0011","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jid.2017.11.035","article-title":"Variability in the expression of immunohistochemical markers: implications for biomarker interpretation in cutaneous t-cell lymphoma","volume":"138","author":"Rahbar","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2022100119173343700_CIT0012","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to brentuximab vedotin versus physician\u2019s choice by cd30 expression and large cell transformation status in patients with mycosis fungoides: an alcanza sub-analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"issue":"32","key":"2022100119173343700_CIT0013","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase ii trial of brentuximab vedotin for cd30+ cutaneous t-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"issue":"20","key":"2022100119173343700_CIT0014","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed t-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2022100119173343700_CIT0015","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory dlbcl with variable cd30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"issue":"10094","key":"2022100119173343700_CIT0016","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in cd30-positive cutaneous t-cell lymphoma (alcanza): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"2022100119173343700_CIT0017","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"2022100119173343700_CIT0018","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PAS.0000000000000571","article-title":"Cd30 expression by b and t cells: a frequent finding in angioimmunoblastic t-cell lymphoma and peripheral t-cell lymphoma-not otherwise specified","volume":"40","author":"Onaindia","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2022100119173343700_CIT0019","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1080\/10428194.2016.1256481","article-title":"Brentuximab vedotin activity in diffuse large b-cell lymphoma with cd30 undetectable by visual assessment of conventional immunohistochemistry","volume":"58","author":"Bartlett","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"2022100119173343700_CIT0020","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess cd30 expression in peripheral t-cell lymphomas: high correlation with mrna levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"issue":"suppl_2","key":"2022100119173343700_CIT0021","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hon.2437_65","article-title":"Brentuximab vedotin vs physician\u2019s choice in ctcl patients from the phase 3 alcanza study: analysis of outcomes by cd30 expression","volume":"35","author":"Kim","year":"2017","journal-title":"Hematol Oncol"},{"issue":"4","key":"2022100119173343700_CIT0022","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.4049\/jimmunol.169.4.1784","article-title":"Cd30 expression identifies the predominant proliferating t lymphocyte population in human alloimmune responses","volume":"169","author":"Chan","year":"2002","journal-title":"J Immunol"},{"issue":"4","key":"2022100119173343700_CIT0023","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ijc.2910600419","article-title":"Shedding of the soluble form of cd30 from the hodgkin-analogous cell line l540 is strongly inhibited by a new cd30-specific antibody (ki-4)","volume":"60","author":"Horn-Lohrens","year":"1995","journal-title":"Int J Cancer"},{"issue":"7","key":"2022100119173343700_CIT0024","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1096\/fj.03-0901fje","article-title":"Ectodomain shedding of cd30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5","volume":"18","author":"Hansen","year":"2004","journal-title":"FASEB J"},{"issue":"6","key":"2022100119173343700_CIT0025","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1200\/JCO.1995.13.6.1355","article-title":"Serum levels of the soluble form of cd30 molecule as a tumor marker in cd30+ anaplastic large-cell lymphoma","volume":"13","author":"Nadali","year":"1995","journal-title":"J Clin Oncol"},{"issue":"2","key":"2022100119173343700_CIT0026","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2141.1990.tb02664.x","article-title":"Serum levels of soluble cd30 molecule (ki-1 antigen) in hodgkin\u2019s disease: relationship with disease activity and clinical stage","volume":"75","author":"Pizzolo","year":"1990","journal-title":"Br J Haematol"},{"issue":"8","key":"2022100119173343700_CIT0027","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"Muller","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"13","key":"2022100119173343700_CIT0028","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1182\/blood-2007-06-097014","article-title":"Macrophages contribute to the antitumor activity of the anti-cd30 antibody sgn-30","volume":"110","author":"Oflazoglu","year":"2007","journal-title":"Blood"},{"issue":"suppl_15","key":"2022100119173343700_CIT0029","doi-asserted-by":"crossref","first-page":"Abstract 2469","DOI":"10.1158\/1538-7445.AM2015-2469","article-title":"Brentuximab vedotin-mediated immunogenic cell death","volume":"75","author":"Gardai","year":"2015","journal-title":"Cancer Res"},{"issue":"suppl_19","key":"2022100119173343700_CIT0030","doi-asserted-by":"crossref","first-page":"Abstract 3694","DOI":"10.1158\/1538-7445.AM2014-3694","article-title":"Relationship between in vivo antitumor activity of adc and payload release in preclinical models","volume":"74","author":"Li","year":"2014","journal-title":"Cancer Res"},{"issue":"suppl_13","key":"2022100119173343700_CIT0031","doi-asserted-by":"crossref","first-page":"Abstract 5588","DOI":"10.1158\/1538-7445.AM2017-5588","article-title":"Brentuximab vedotin-driven immunogenic cell death enhances antitumor immune responses, and is potentiated by pd1 inhibition in vivo","volume":"77","author":"Cao","year":"2017","journal-title":"Cancer Res"},{"issue":"9","key":"2022100119173343700_CIT0032","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res"},{"issue":"3","key":"2022100119173343700_CIT0033","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","article-title":"Intracellular activation of sgn-35, a potent anti-cd30 antibody-drug conjugate","volume":"16","author":"Okeley","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"suppl_13","key":"2022100119173343700_CIT0034","doi-asserted-by":"crossref","first-page":"Abstract 1789","DOI":"10.1158\/1538-7445.AM2018-1789","article-title":"Cd30+t regulatory cells, but not cd30+cd8 t cells, are impaired following brentuximab vedotin treatment in vitro and in vivo","volume":"78","author":"Heiser","year":"2018","journal-title":"Cancer Res"},{"issue":"suppl_13","key":"2022100119173343700_CIT0035","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"issue":"suppl_1","key":"2022100119173343700_CIT0036","doi-asserted-by":"crossref","first-page":"Abstract 130","DOI":"10.1182\/blood-2019-126787","article-title":"Safety and efficacy of brentuximab vedotin in combination with avd in stage ii-iv hiv-associated classical hodgkin lymphoma: results of the phase 2 study, amc 085","volume":"134","author":"Rubinstein","year":"2019","journal-title":"Blood"},{"issue":"suppl_1","key":"2022100119173343700_CIT0037","first-page":"Abstract 2976","article-title":"Trial-in-progress: frontline brentuximab vedotin and chp (a+chp) in patients with peripheral t-cell lymphoma with less than 10% cd30 expression","volume":"136","author":"Jagadeesh","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2022100119173343700_CIT0038","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1634\/theoncologist.2019-0098","article-title":"Fda approval summary: brentuximab vedotin in first-line treatment of peripheral t-cell lymphoma","volume":"24","author":"Richardson","year":"2019","journal-title":"Oncologist"},{"key":"2022100119173343700_CIT0039","doi-asserted-by":"crossref","DOI":"10.5858\/arpa.2021-0270-OA","article-title":"Best practices in cd30 immunohistochemistry testing, interpretation, and reporting.","author":"Gru","year":"2022","journal-title":"Arch Pathol Lab Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/10\/864\/46284914\/oyac137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/10\/864\/46284914\/oyac137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T19:19:05Z","timestamp":1664651945000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/10\/864\/6659958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,8,10]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac137","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,8,10]]}}}